1. Association AP. Understanding Mental Disorders: Your Guide to DSM-5-TR®: American Psychiatric Pub; 2023.

2. Nazari z, foroozandeh e, banitaba m. The Effectiveness of Autobiographical Memory Training on Cognitive Abilities, Emotion Regulation, and Emotional Dysphoria in Depressed Adolescent Girls. The Neuroscience Journal of Shefaye Khatam. 2022; 10(4): 62-70. [DOI:10.52547/shefa.10.4.62]

3. Bandelow B, Schmahl C, Falkai P, Wedekind D, Crockett C, Sackett G, et al. American Psychiatric Association. DSM-5 Task Force.(2013). Diagnostic and statistical manual of mental disorders: Dsm-5 . Washington, DC: American Psychiatric Association. Bachevalier, J., Meunier, M., Lu, MX, & Ungerleider, LG (1997). Thalamic and temporal cortex input to medial prefrontal cortex in rhesus monkeys. Exp Brain Res, 115 (3). Examination of Opioid and Glucocorticoid Receptor Pathways in Rhesus Macaques (Macaca mulatta) Exhibiting Self-Injurious Behaviors. 2017;100(8):11.

4. Isanazar A, Joukar F, Maroufizadeh S, Faraji N, Zeinali T, Soleimani R, et al. Prevalence of depression and associated factors among adults: the PERSIAN Guilan cohort study (PGCS). Journal of Public Health. 2024; 32(7): 1187-95. [DOI:10.1007/s10389-023-01898-1]

5. Mohammad Nia S, Mashhadi A. The Effect of Meaning of life on the Relationship between Attitude toward Substance Abuse and Depression. The Neuroscience Journal of Shefaye Khatam. 2018;6(3):43-51. [DOI:10.29252/shefa.6.3.43]

6. Zhao Y, Yin J, Zhang L, Zhang Y, Chen X. Drug-drug interaction prediction: databases, web servers and computational models. Brief Bioinform. 2023; 25(1). [DOI:10.1093/bib/bbad445]

7. Hines LE, Malone DC, Murphy JE. Recommendations for generating, evaluating, and implementing drug‐drug interaction evidence. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2012; 32(4): 304-13. [DOI:10.1002/j.1875-9114.2012.01024.x]

8. Chen Y, Ding L. Potential drug-drug interactions in outpatients with depression of a psychiatry department. Saudi Pharmaceutical Journal. 2023; 31(2): 207-13. [DOI:10.1016/j.jsps.2022.12.004]

9. Gold SM, Köhler-Forsberg O, Moss-Morris R, Mehnert A, Miranda JJ, Bullinger M, et al. Comorbid depression in medical diseases. Nature Reviews Disease Primers. 2020; 6(1): 69. [DOI:10.1038/s41572-020-0200-2]

10. Aronson J. Communicating information about drug interactions. British journal of clinical pharmacology. 2007; 63(6): 637. [DOI:10.1111/j.1365-2125.2007.02948.x]

11. Garcia-Cortes M, Robles-Diaz M, Stephens C, Ortega-Alonso A, Lucena MI, Andrade RJ. Drug induced liver injury: an update. Archives of Toxicology. 2020; 94: 3381-407. [DOI:10.1007/s00204-020-02885-1]

12. Davies LE, Spiers G, Kingston A, Todd A, Adamson J, Hanratty B. Adverse outcomes of polypharmacy in older people: systematic review of reviews. Journal of the American Medical Directors Association. 2020; 21(2): 181-7. [DOI:10.1016/j.jamda.2019.10.022]

13. Soherwardi S, Chogtu B, Faizal P. Surveillance of the Potential Drug-Drug Interactions in the Medicine Department of a Tertiary Care Hospital. Journal of Clinical & Diagnostic Research. 2012; 6(7).

14. FDA US. Drug-Drug Interactionces Guidances: U.S. FOOD & DRUG ADMINISTRATION; 2024 [Available from: https://www.fda.gov/drugs/drug-interactions-labeling/drug-interactions-relevant-regulatory-guidance-and-policy-documents.

15. Cole S, Kerwash E, Andersson A. A summary of the current drug interaction guidance from the European Medicines Agency and considerations of future updates. Drug Metabolism and Pharmacokinetics. 2020; 35(1): 2-11. [DOI:10.1016/j.dmpk.2019.11.005]

16. Zhao M, Ma J, Li M, Zhang Y, Jiang B, Zhao X, et al. Cytochrome P450 enzymes and drug metabolism in humans. International journal of molecular sciences. 2021; 22(23): 12808. [DOI:10.3390/ijms222312808]

17. Koohpayezadeh F, Motamdi M, Eskandari H, Farrokhi N. Effectiveness of a psychological-educational package based on the logo therapy on loneliness and self-efficacy of retired teachers. Journal of Gerontology. 2019; 4(2): 24-33. [DOI:10.29252/joge.4.1.24]

18. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Bmj. 2021; 372:n71. [DOI:10.1136/bmj.n71]

19. Semnani KM, Saeedi M, Mashinchi MI. Evaluation of Anti-depressant Drugs Interactions in Insured Prescriptions in Anzali in 1379. Journal Of Guilan University Of Medical Sciences. 2002; 11(41): 26-33.

20. Esteghamat SS, Esteghamat SS, Bastani F, Kazemi H, Koulivand P, Bayan L, Gorji A. Potential drug interactions in war-injured veterans with Psychaitric disorders. Iranian Journal of War and Public Health. 2012; 4(13): 23.

21. Gorji A, Gharakhani M, Jahromi SR, Sadeghian H, Faghihzadeh S, Kazemi H, et al. Multiple drug interactions in war-injured veterans. Iranian Journal of War and Public Health. 2010; 2(8): 23.

22. Dagnew EM, Ergena AE, Wondm SA, Sendekie AK. Potential drug-drug interactions and associated factors among admitted patients with psychiatric disorders at selected hospitals in Northwest Ethiopia. BMC Pharmacology and Toxicology. 2022; 23(1): 88. [DOI:10.1186/s40360-022-00630-1]

23. Satoskar R, Rege N, Bhandarkar S. Pharmacology and pharmacotherapeutics: Elsevier Health Sciences; 2017.

24. Coelho PV, Brum Cde A. Interactions between antidepressants and antihypertensive and glucose lowering drugs among patients in the HIPERDIA Program, Coronel Fabriciano, Minas Gerais State, Brazil. Cad Saude Publica. 2009; 25(10): 2229-36. [DOI:10.1590/S0102-311X2009001000013]

25. Dongre K, Jungo A, Späni S, Zysset Y, Leuppi-Taegtmeyer A. Disease-Drug Interactions Requiring Special Attention. Praxis (Bern 1994). 2022; 111(12): 700-5. [DOI:10.1024/1661-8157/a003923]

26. Mousavi B, Seyed Hoseini Davarani SH, Soroush M, Jamali A, Khateri S, Talebi M, Montazeri A. Quality of life in caregivers of severely disabled war survivors. Rehabil Nurs. 2015; 40(3): 139-47. [DOI:10.1002/rnj.159]

27. Zheng WY, Richardson L, Li L, Day R, Westbrook J, Baysari M. Drug-drug interactions and their harmful effects in hospitalised patients: a systematic review and meta-analysis. European journal of clinical pharmacology. 2018; 74(1): 15-27. [DOI:10.1007/s00228-017-2357-5]

28. Mousavi B, Maftoon F, Soroush M, Mohammad K, Majdzadeh R. Health care utilization and expenditure in war survivors. Archives of Iranian medicine. 2020; 23(4Suppl1): S9-S15. [DOI:10.34172/aim.2020.s3]

29. Mousavi B, Soroush M, Maftoon F, Mohammad K, Ayoubian A. Satisfaction of supplementary insurance for medicinal services in war survivors in Iran. Med J Islam Repub Iran. 2019; 33: 66. [DOI:10.47176/mjiri.33.66]

30. Lau L, Bagri H, Legal M, Dahri K. Comparison of clinical importance of drug interactions identified by hospital pharmacists and a local clinical decision support system. The Canadian Journal of Hospital Pharmacy. 2021; 74(3): 203. [DOI:10.4212/cjhp.v74i3.3147]

31. Kaboli PJ, Hoth AB, McClimon BJ, Schnipper JL. Clinical pharmacists and inpatient medical care: a systematic review. Archives of internal medicine. 2006;166(9): 955-64. [DOI:10.1001/archinte.166.9.955]

32. Woody C, Ferrari A, Siskind D, Whiteford H, Harris M. A systematic review and meta-regression of the prevalence and incidence of perinatal depression. Journal of affective disorders. 2017; 219: 86-92. [DOI:10.1016/j.jad.2017.05.003]

33. World Health Organization Depressive disorder (depression) 2023 [https://www.who.int/news-room/fact-sheets/detail/depression#:~:text=An%20estimated%203.8%25%20of%20the,among%20women%20than%20among%20men.

34. Tahan M, Saleem T, Zygoulis P, Pires LVL, Pakdaman M, Taheri H, Ebrahimpour M. A systematic review of prevalence of Depression in Iranian patients. Neuropsychopharmacol Hung. 2020; 22(1): 16-22.

35. Yalçın N, Özdemir N, Cak Esen HT, Çengel Kültür SE, Demirkan K. Potential drug‐drug interactions with psychotropic drugs in paediatric inpatients: A cross‐sectional study. International journal of clinical practice. 2021; 75(6): e14107. [DOI:10.1111/ijcp.14107]

36. Lai LL, Alvarez G, Dang L, Vuong D, Ngo V, Jo Y, Koh L. Prevalence and trend of potential drug-drug interaction among children with depression in US outpatient settings. Journal of Pharmaceutical Health Services Research. 2019; 10(4): 393-9. [DOI:10.1111/jphs.12320]

37. Chen Y, Ding L. Potential drug-drug interactions in outpatients with depression of a psychiatry department. Saudi Pharm J. 2023; 31(2): 207-13. [DOI:10.1016/j.jsps.2022.12.004]